Publications by authors named "David Thein"
Background: Hospitalizations are a major burden for both patients and society but are potentially preventable. We examined the one-year hospitalization burden in patients undergoing transcatheter aortic valve replacement (TAVR) and compared hospitalization rates and patterns with those undergoing isolated surgical aortic valve replacement (SAVR).
Methods: Using Danish nationwide registries, we identified patients who underwent first-time TAVR and isolated SAVR (2008-2019), respectively.
Article Synopsis
- - The study aimed to determine how a patient's treatment journey before starting biologic drugs affects the durability of those treatments for psoriasis, utilizing data from Danish national registries over a period from 2010 to 2021.
- - 2496 patients were analyzed, with a majority on adalimumab, and results showed that about 78.2% discontinued treatment during an average follow-up of 5 years.
- - Ultimately, the study concluded that the complexity of the pre-biologic treatment journey did not have a significant impact on the survival rate of biologic drugs in these patients.
Importance: Alopecia areata (AA) carries a psychological burden for patients beyond hair loss. However, quality-of-life measurement tools such as EQ-5D used in clinical trials may not adequately capture the burden of AA, the perceived stigmatization or the psychosocial impact of AA.
Objective: To investigate the potential association between disease severity and the degree of social isolation, perceived stigmatization, anxiety and depression, alcohol consumption and work absenteeism using multiple PRO measures in patients with AA.
Background: Flare patterns are not routinely considered in the severity classification or in clinical decision-making of atopic dermatitis (AD), but frequent or severe flares may contribute considerably to the disease burden.
Objectives: To characterize patients with AD in relation to their flare pattern and compare flare patterns to disease severity, life quality and treatment satisfaction.
Methods: Patients with AD from the Danish Skin Cohort were included if they had active AD with and available data on number of flare-ups within the last 12 months.
Background: Topical corticosteroids (TCS) are used to treat most patients with chronic hand eczema (CHE), but knowledge about TCS-related adverse events in CHE is limited.
Objectives: To investigate patient-reported adverse events to TCS in CHE patients.
Methods: Data on adverse events related to TCS use in patients with CHE were analyzed from the Danish Skin Cohort; a prospective survey of a hospital cohort.
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis. This cross-sectional study used the Danish national registers and Danish Skin Cohort to assess the prevalence of risk factors that potentially impact choice of treatment with oral Janus kinase inhibitors in adult patients with atopic dermatitis. From the Danish national registers and Danish Skin Cohort, 18,618 and 3,573 adults with atopic dermatitis, respectively, were identified.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to validate hand eczema (HE) ICD-10 codes in the Danish National Patient Registry and assess patient characteristics, lifestyle factors, and medication use.
- Nineteen HE ICD-10 codes were validated, showing high predictive values, while highlighting that HE patients tend to be middle-aged women with a history of atopy and smoking.
- The research found that HE patients received nearly double the prescriptions for topical corticosteroids compared to the general population, emphasizing significant differences in treatment needs.
Article Synopsis
- The study aimed to evaluate the real-world effectiveness of biologics in treating psoriasis by looking at treatment discontinuation and off-label dose escalation, rather than relying solely on traditional drug survival studies.
- Researchers analyzed data from a nationwide registry (DERMBIO) involving patients treated with adalimumab, secukinumab, and ustekinumab from 2007 to 2019, focusing on composite, discontinuation, and escalation outcomes.
- Findings indicated that secukinumab had a lower overall risk of treatment discontinuation compared to ustekinumab, but a higher risk for discontinuation when compared to adalimumab, with bio-naive patients on secukinumab showing a similar discontinuation risk as those
Importance: Tumor necrosis factor-α inhibitor (TNFi)-associated psoriasis is a rare adverse event following TNFi treatment. Data on the risk of developing TNFi-associated psoriasis when treated with TNFi are sparse.
Objective: To investigate the associated risk between new-onset psoriasis and TNFi treatment compared with nonbiologic conventional treatment.
The glycome undergoes characteristic changes during histogenesis and organogenesis, but our understanding of the importance of select glycan structures for tissue formation and homeostasis is incomplete. Here, we present a human organotypic platform that allows genetic dissection of cellular glycosylation capacities and systematic interrogation of the roles of distinct glycan types in tissue formation. We used CRISPR-Cas9 gene targeting to generate a library of 3D organotypic skin tissues that selectively differ in their capacity to produce glycan structures on the main types of N- and O-linked glycoproteins and glycolipids.
View Article and Find Full Text PDFBackground: In randomised clinical trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduced cardiovascular events in patients with type 2 diabetes (T2D) at high cardiovascular risk, as compared to standard care. However, data comparing these agents in patients with T2D who are at moderate risk is sparse.
Methods: From Danish national registries, we included patients with T2D previously on metformin monotherapy, who started an additional glucose-lowering agent [GLP-1 RA, SGLT-2 inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitor, sulfonylurea (SU), or insulin] in the period 2010-2016.